MRK ▼ -0.3% - Merck & Co., Inc. $MRK - Merck’s Remigromig, a Tri-specific Agonist of the Wingless-related Integration Site (Wnt) Pathway, Met Primary Endpoint in the Pivotal Phase 2b/3 BRUNELLO Study of Adults with Diabetic Macular Edema 24-SEP-2026 06:50 AM ET